Unlikely to cause harm — often a labeling or packaging issue.
Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.
| Distributed by / for | Jubilant Cadista Pharmaceuticals, Inc. |
| NDC | 59746-317-60 |
| Full product label | BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, packaged in a) 60-count bottles (NDC 59746-317-60) and b) 100-count bottles (NDC 59746-317-01), Rx only, Manufactured by: Julibant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA. |
| Recalling firm | Jubilant Cadista Pharmaceuticals, Inc. |
| Distribution | Nationwide in the USA |
| Quantity | 19,682 bottles |
| Recall initiated | 2016-04-08 |
| Report date | 2017-04-19 |
| Recall completed | 2017-04-17 |
| Recall number | D-0671-2017 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Salisbury MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗